Edition:
United States

InVivo Therapeutics Holdings Corp (NVIV.OQ)

NVIV.OQ on NASDAQ Stock Exchange Global Market

0.52USD
16 Feb 2018
Change (% chg)

-- (--)
Prev Close
$0.52
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
38,622
52-wk High
$4.55
52-wk Low
$0.45

Latest Key Developments (Source: Significant Developments)

InVivo Therapeutics Appoints Richard Toselli As Chief Executive Officer
Monday, 5 Feb 2018 08:00am EST 

Feb 5 (Reuters) - Invivo Therapeutics Holdings Corp ::INVIVO THERAPEUTICS ANNOUNCES APPOINTMENT OF RICHARD TOSELLI, M.D., AS PRESIDENT AND CHIEF EXECUTIVE OFFICER.INVIVO THERAPEUTICS - ‍TOSELLI HAS BEEN APPOINTED TO BOARD AND WILL CONTINUE TO SERVE IN HIS CAPACITY AS INVIVO'S CHIEF MEDICAL OFFICER​.INVIVO THERAPEUTICS HOLDINGS CORP - RICHARD TOSELLI HAS BEEN APPOINTED PRESIDENT AND CEO OF INVIVO.  Full Article

InVivo Therapeutics Announces Latest Results From INSPIRE
Wednesday, 3 Jan 2018 08:00am EST 

Jan 3 (Reuters) - InVivo Therapeutics Holdings Corp ::INVIVO THERAPEUTICS ANNOUNCES LATEST RESULTS FROM INSPIRE AND PROVIDES UPDATE ON PROPOSED CLINICAL PATH FORWARD.INVIVO THERAPEUTICS HOLDINGS - 19 PATIENTS IMPLANTED WITH NEURO-SPINAL SCAFFOLD;3 PATIENTS DIED WITHIN 2 WEEKS OF IMPLANTATION​ IN STUDY.INVIVO THERAPEUTICS HOLDINGS CORP - ‍16 EVALUABLE PATIENTS HAVE NOW ALL REACHED SIX-MONTH PRIMARY ENDPOINT VISIT IN STUDY​.INVIVO THERAPEUTICS - ‍DOES NOT ANTICIPATE REOPENING ENROLLMENT IN INSPIRE,EXPECTS TO PROVIDE ADDITIONAL CLARITY ON CLINICAL PATH FORWARD IN Q2 2018​.  Full Article

InVivo Therapeutics Announces Executive Management And Board Changes
Monday, 18 Dec 2017 08:00am EST 

Dec 18 (Reuters) - InVivo Therapeutics Holdings Corp ::INVIVO THERAPEUTICS ANNOUNCES EXECUTIVE MANAGEMENT AND BOARD CHANGES.INVIVO THERAPEUTICS HOLDINGS CORP - ‍RICHARD TOSELLI, NAMED ACTING CHIEF EXECUTIVE OFFICER​.INVIVO THERAPEUTICS HOLDINGS CORP - ‍ TOSELLI REPLACES MARK PERRIN, WHO HAS RESIGNED AS CEO AND CHAIRMAN OF INVIVO'S BOARD OF DIRECTORS​.INVIVO THERAPEUTICS HOLDINGS CORP - ‍ TOSELLI WILL CONTINUE TO SERVE IN HIS CAPACITY AS INVIVO'S CHIEF MEDICAL OFFICER​.INVIVO THERAPEUTICS HOLDINGS CORP - ANN MERRIFIELD WAS APPOINTED AS CHAIR OF BOARD OF DIRECTORS​.  Full Article

InVivo Therapeutics reports Q3 loss per share $0.28
Monday, 30 Oct 2017 04:45pm EDT 

Oct 30 (Reuters) - InVivo Therapeutics Holdings Corp :InVivo Therapeutics provides business update and reports 2017 third quarter financial results.Q3 adjusted loss per share $0.19 excluding items.Q3 loss per share $0.28.  Full Article

InVivo Therapeutics Holdings Corp - ‍ expects restructuring to be substantially completed by end of Q3 2017
Monday, 28 Aug 2017 04:50pm EDT 

Aug 28 (Reuters) - InVivo Therapeutics Holdings Corp :InVivo Therapeutics Holdings Corp - ‍ expects restructuring to be substantially completed by end of Q3 2017, to be fully completed by end of Q4 of 2017​.InVivo Therapeutics Holdings Corp says ‍restructuring is expected to extend company's cash runway into beginning of Q3 of 2018 - SEC filing​.InVivo Therapeutics Holdings - ‍expects restructuring will result in total restructuring charges of about $810,000-$1.1 million during year ending Dec 31, 2017.InVivo Therapeutics Holdings-on Aug 28, co notified Thomas Ulich, co's chief scientific officer,that his employment to be terminated effective Aug 30, 2017​.  Full Article

Invivo Therapeutics reports strategic corporate restructuring
Monday, 28 Aug 2017 04:30pm EDT 

Aug 28 (Reuters) - Invivo Therapeutics Holdings Corp ::Invivo Therapeutics announces strategic corporate restructuring.Invivo Therapeutics - ‍company is undergoing a reduction in force (rif), in which it is eliminating 13 positions, or approximately 39 pct of its workforce​.Invivo Therapeutics - ‍company is evaluating strategic options for allowing cell and gene therapy programs to move forward outside of company​.Invivo Therapeutics Holdings Corp - ‍plans to restart cervical study once FDA approves a protocol that allows for enrollment in united states​.Invivo Therapeutics Holdings- ‍as part of decision to focus on inspire, announced suspension of chronic sci stem cell, gene therapy research programs​.Invivo Therapeutics- ‍as part of decision to focus on inspire, also announced halt in enrollment into canadian cervical study of neuro-spinal scaffold​.Invivo Therapeutics Holdings - ‍restructuring actions all together are projected to result in 2018 operating expense savings of approximately $7.3 million​.Invivo Therapeutics Holdings -restructuring actions all together projected to reduce 2018 cash burn from about $2.0 million/month to about $1.5 million/month.  Full Article

InVivo Therapeutics Holdings Q2 adjusted loss per share $0.22 excluding items
Tuesday, 8 Aug 2017 06:00pm EDT 

Aug 8 (Reuters) - Invivo Therapeutics Holdings Corp :InVivo Therapeutics Holdings provides business update and reports 2017 second quarter financial results.Q2 adjusted loss per share $0.22 excluding items.Q2 loss per share $0.20.InVivo Therapeutics Holdings - ‍company ended quarter with $21.8 million of cash, cash equivalents, and marketable securities​.  Full Article

Invivo Therapeutics announces positive resultsin the study of the neuro-spinal Scaffold
Wednesday, 28 Jun 2017 08:00am EDT 

June 28 (Reuters) - Invivo Therapeutics Holdings Corp :Invivo Therapeutics announces positive motor recovery assessments in two patients in the inspire study of the neuro-spinal Scaffold.Continued improvement from AIS B to AIS C for two patients with early conversions.  Full Article

Invivo Therapeutics reports Q1 loss per share $0.20
Thursday, 4 May 2017 04:36pm EDT 

May 4 (Reuters) - Invivo Therapeutics Holdings Corp :Invivo Therapeutics provides clinical update and reports 2017 first quarter financial results.Q1 adjusted loss per share $0.21 excluding items.Q1 loss per share $0.20.  Full Article

Invivo Therapeutics appoints Christopher Mcnulty as CFO
Wednesday, 29 Mar 2017 08:00am EDT 

Invivo Therapeutics Holdings Corp : Invivo Therapeutics appoints Christopher Mcnulty as chief financial officer . Mcnulty will be taking over for interim CFO, Melanie Morel-Ferris .Melanie Morel-Ferris will remain as company's senior director, finance and controller.  Full Article

BRIEF-InVivo Therapeutics Appoints Richard Toselli As Chief Executive Officer

* INVIVO THERAPEUTICS ANNOUNCES APPOINTMENT OF RICHARD TOSELLI, M.D., AS PRESIDENT AND CHIEF EXECUTIVE OFFICER